PBAC's latest decision on Metformin and sitagliptin: Recommended (2013). Considered for Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, for initiation of a dipeptidyl peptidase 4 inhibitor, thiazolidinedione, or glucagon-like peptide-1 where metformin and sulfonylurea combination is contraindicated or not tolerated.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Adult patients with Type 2 diabetes mellitus whose HbA1c is greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is contraindicated or not tolerated, requiring initiation of a gliptin, glitazone, or glucagon-like peptide-1.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
Single-arm
Primary endpoint
Surrogate
Pivotal trial size
140 patients
Key trials
P147, P300, P317, P164, P165
Comparator
alogliptin with metformin fixed dose combination; also metformin immediate release/sitagliptin FDC and individual components of sitagliptin and metformin XR
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER range reported as this was not a cost-utility analysis